[Evaluation using dynamic ECG of the effects of reproterol (a new beta-2 adrenergic receptor agonist) on the heart conduction system].
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D004341:Drug Evaluation; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy; D009921:Metaproterenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000150:complications; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004338:Drug Combinations; C014792:reproterol; D009921:Metaproterenol; D013806:Theophylline
Valutazione dell'ECG dinamico degli effetti del reproterolo (un nuovo agonista dei recettori beta-2-adrenergici) sul sistema di eccitoconduzione cardiaco.